MEDFORD, MA--(Marketwired - March 11, 2014) - Hepregen Corporation, a leader in the development of next generation HepatoPac™ and HepatoMune™ cell-based in vitro assay products, announced today the commercial launch of the Company's first HepatoPac™ kit designed specifically for use in evaluating metabolic turnover of chemicals in the human liver. The kit contains one or more standard 96-well tissue culture plates featuring specially configured micro-patterned human liver cells co-cultured with stromal cells. The liver cells (hepatocytes) on these plates remain metabolically active for up to 35 days. Using this plug-in-ready kit, industrial product developers can accurately evaluate metabolic turnover of chemicals regardless of whether they are rapidly or very slowly metabolized by the liver.
Jack McGeehan, Hepregen's Vice President of Operations, stated, "The launch of this specially configured product so soon after the recent launch of the Company's monkey HepatoPac™ kit for metabolite identification and profiling demonstrates the flexibility of Hepregen's platform technology. This product launch provides another demonstration of our ability to rapidly develop and launch new application-directed products."
Dr. Vincent Zurawski, Hepregen's Chief Executive Officer, added, "During the product development process, data generated from this new HepatoPac™ kit was used to predict drug clearance from the circulation with a high degree of in vitro/in vivo correlation when compared to clinical findings." Dr. Zurawski also stated, "The launch of this new kit demonstrates Hepregen's commitment to providing its customers with unique problem-solving tools. The launch adds another product to the Company's portfolio, which includes human, rat, monkey, human triple-donor and rat-human HepatoPac™ application-directed kits for metabolite identification and profiling."
About Hepregen Corporation
Hepregen Corporation is a leader in innovating unique and proprietary bioengineered micro-liver platforms for use in environmental testing, preventive care, and product development in the pharmaceutical and biopharmaceutical, diagnostic, cosmetics, and chemical industries. The Company's micro-liver HepatoPac™ and HepatoMune™ cell-based assays are designed to drive a paradigm shift in drug development. The utility of Hepregen's human, rat, monkey, dog, and multi-species/multi-donor HepatoPac™
and HepatoMune™ application-directed products has been validated in collaboration with investigators at several well-known pharmaceutical companies. Additionally, new applications for these products are being tested by Hepregen, its pharmaceutical company customers, and its academic and business partners. Hepregen was founded and capitalized by Battelle Ventures and Innovation Valley Partners with technology licensed from the Massachusetts Institute of Technology. The technology was developed by Professor Sangeeta Bhatia, who is a world renowned expert and leader in liver bioengineering for life science and therapeutic applications.
Image Available: http://www.marketwire.com/library/MwGo/2014/3/10/11G013142/Images/Capture-1281700987308.JPG